Systemic treatment within  days before the first dose of study drugs, or concurrent use, with any of the following:\r\n* Strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin)\r\n* Strong inhibitors of family CYP family , subfamily A (A) (telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole)\r\n* Strong CYPA polypeptide  () inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, Ginkgo biloba or St. Johns wort)
Systemic treatment, within  days before the first dose of ixazomib, with strong inhibitors of CYPA (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYPA (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Systemic treatment, within  days before the first dose of ixazomib, with strong inhibitors of CYPA (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Systemic treatment with strong inhibitors of CYPA (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYPA (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole), or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or use of Ginkgo biloba or St. John's wort within  days before randomization.
Systemic treatment, within  days before the first dose of MLN, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin), strong inhibitors of cytochrome P, family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort; ciprofloxacin should not be administered for at least  days before MLN  administration; extended release ciprofloxacin should not be administered for at least  days prior to MLN  administration
Systemic treatment, within  days before the first dose of ixazomib, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  gene (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P, family , subfamily A gene locus (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Systemic treatment, during or within  hours of the first dose of MLN, strong inhibitors of cytochrome P family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort; for this protocol prophylactic antibiotics are not recommended, at least not until  hours after the last dose of study drug (given on day ), when the patient may be neutropenic.; for patients with fever and/or infections, cefepime and AmBisome are acceptable
Systemic treatment, within  days before the first dose of ixazomib, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P, family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Systemic treatment, within  days before the first dose of MLN, with strong inhibitors of CYPA (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYPA (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of ginkgo biloba or St. Johns wort
Systemic treatment, within  days before the first dose of ixazomib, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P, family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of ginkgo biloba or St. Johns wort
Systemic treatment with strong inhibitors of CYPA (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, Gingko biloba, St. Johns wort) are not allowed =<  days before registration
Systemic treatment, within  days before the first dose of MLN, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P, family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Systemic treatment, within  days before study enrollment, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P, family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Systemic treatment, within  days before the first dose of MLN, with strong inhibitors of cytochrome , family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of ginkgo biloba or St. Johns wort
Systemic treatment, within  days before study enrollment, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P, family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort
Systemic treatment, within  days before the first dose of ixazomib, with strong inhibitors of CYPA (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome CYPA (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Systemic treatment, within  days before the first dose of MLN (ixazomib citrate), with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P, family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of ginkgo biloba or St. Johns wort
Systemic treatment with strong inhibitors of cytochrome Ps (CYP)A (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYPA (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within  days before randomization in the study.
Systemic treatment, within  days before the first dose of MLN, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P, family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Concurrent use of strong cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors (e.g. clarithromycin, grapefruit juice, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin, and voriconazole); or strong CYPA inducers (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, and St. Johns wort)
Systemic treatment with strong inhibitors of CYPA (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYPA (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within  days before randomization in the study
Systemic treatment, within  days before study enrollment, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort
Systemic treatment with strong inhibitors of cytochrome P (CYP) A (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYPA (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within  days before randomization in the study.
Systemic treatment, within  days before the first dose of Ixazomib, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P, family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of ginkgo biloba or St. Johns wort
Systemic treatment, within  days, or the half-life of the treatment, whichever is longer before the first dose of MLN, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P, family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Systemic treatment, within  days before the first dose of MLN, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P, family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Systemic treatment, within  days before the first dose of MLN, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P, family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Systemic treatment, within  days before the first dose of ixazomib, with strong inhibitors of CYPA (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYPA (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of ginkgo biloba or St. John's wort
Systemic treatment, within  days before the first dose of ixazomib, with strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P, family , subfamily A (CYPA) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of ginkgo biloba or St. Johns wort
